Back to GetFilings.com
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For Quarterly Period Ended April 30, 2003
[_] Transition Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the Transition Period from _________ to __________
Commission File Number 1-8597
The Cooper Companies, Inc.
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 94-2657368
- ------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
6140 Stoneridge Mall Road, Suite 590, Pleasanton, CA 94588
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (925) 460-3600
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Act).
Yes [X] No [ ]
Indicate the number of shares outstanding of each of issuer's classes of common
stock, as of the latest practicable date.
Common Stock, $.10 Par Value 31,119,498 Shares
- ----------------------------- ---------------------------
Class Outstanding at May 31, 2003
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
INDEX
Page No.
--------
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Consolidated Condensed Statements of Income - Three
and Six Months Ended April 30, 2003 and 2002 3
Consolidated Condensed Balance Sheets - April 30, 2003
and October 31, 2002 4
Consolidated Condensed Statements of Cash Flows - Six
Months Ended April 30, 2003 and 2002 5
Consolidated Condensed Statements of Comprehensive
Income - Three and Six Months Ended April 30, 2003 and 2002 6
Notes to Consolidated Condensed Financial Statements 7
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations 15
Item 3. Quantitative and Qualitative Disclosure About Market Risk 29
Item 4. Controls and Procedures 29
PART II. OTHER INFORMATION
Item 1. Legal Proceedings 30
Item 4. Submission of Matters to a Vote of Security Holders 30
Item 6. Exhibits and Reports on Form 8-K 31
Signature 32
Certifications 33
Index of Exhibits 35
2
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Statements of Income
(In thousands, except for per share amounts)
(Unaudited)
Three Months Ended Six Months Ended
April 30, April 30,
------------------ -------------------
2003 2002 2003 2002
------- ------- -------- --------
Net sales $96,368 $71,910 $190,382 $130,022
Cost of sales 33,948 27,746 68,595 48,373
------- ------- -------- --------
Gross profit 62,420 44,164 121,787 81,649
Selling, general and administrative expense 39,590 28,171 77,467 51,384
Research and development expense 1,279 918 2,594 1,775
Amortization of intangibles 399 392 755 700
------- ------- -------- --------
Operating income 21,152 14,683 40,971 27,790
Interest expense 1,688 1,441 3,512 2,334
Other income (expense), net 818 (18) 1,296 1,018
------- ------- -------- --------
Income before income taxes 20,282 13,224 38,755 26,474
Provision for income taxes 5,071 3,306 9,689 7,151
------- ------- -------- --------
Net income $15,211 $ 9,918 $ 29,066 $ 19,323
======= ======= ======== ========
Earnings per share:
Basic $ 0.49 $ 0.33 $ 0.94 $ 0.63
======= ======= ======== ========
Diluted $ 0.48 $ 0.32 $ 0.92 $ 0.62
======= ======= ======== ========
Number of shares used to compute earnings
per share:
Basic 31,003 30,487 30,953 30,452
======= ======= ======== ========
Diluted 31,789 31,128 31,696 31,095
======= ======= ======== ========
See accompanying notes.
3
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Balance Sheets
(Unaudited)
April 30, October 31,
2003 2002
--------- -----------
(In thousands)
ASSETS
Current assets:
Cash and cash equivalents $ 11,895 $ 10,255
Trade receivables, net 76,792 74,545
Marketable securities 4,469 2,750
Inventories 81,977 76,279
Deferred tax asset 16,426 17,781
Other current assets 19,004 17,300
-------- --------
Total current assets 210,563 198,910
-------- --------
Property, plant and equipment, net 98,270 87,944
Goodwill, net 251,741 238,966
Other intangible assets, net 14,337 14,651
Deferred tax asset 21,055 26,806
Other assets 4,199 3,838
-------- --------
$600,165 $571,115
======== ========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Short-term debt $ 20,636 $ 36,333
Accounts payable 15,481 15,212
Accrued acquisition costs 17,631 24,773
Accrued income taxes 10,592 12,261
Other current liabilities 39,307 38,102
-------- --------
Total current liabilities 103,647 126,681
Long-term debt 141,942 127,318
Other liabilities 1,432 5,674
-------- --------
Total liabilities 247,021 259,673
-------- --------
Stockholders' equity:
Common stock, $.10 par value 3,171 3,153
Additional paid-in capital 288,695 285,619
Accumulated other comprehensive income (loss) 5,833 (4,396)
Retained earnings 65,375 37,236
Unearned compensation (172) (78)
Treasury stock at cost (9,758) (10,092)
-------- --------
Total stockholders' equity 353,144 311,442
-------- --------
$600,165 $571,115
======== ========
See accompanying notes.
4
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Statements of Cash Flows
(In thousands)
(Unaudited)
Six Months Ended
April 30,
-------------------
2003 2002
-------- --------
Cash flows from operating activities:
Net income $ 29,066 $ 19,323
Depreciation and amortization 5,948 5,145
Net (increase) decrease in operating capital (9,069) 5,166
Net decrease in non-current assets 5,684 508
Net decrease in non-current liabilities (2,742) (5,258)
Increase (decrease) in other 1,256 (202)
-------- --------
Net cash provided by operating activities 30,143 24,682
-------- --------
Cash flows from investing activities:
Purchases of property, plant and equipment (13,406) (11,992)
Acquisitions of businesses (38,525) (45,373)
Sale of marketable securities -- 4,057
Other (20) (37)
-------- --------
Net cash used by investing activities (51,951) (53,345)
-------- --------
Cash flows from financing activities:
Net repayments of short-term debt (2,579) (915)
Repayments of long-term debt (44,527) (13,765)
Proceeds from long-term debt 67,700 46,477
Dividends on common stock (927) (761)
Exercises of stock options 3,340 1,976
Other (85) 47
-------- --------
Net cash provided by financing activities 22,922 33,059
-------- --------
Effect of exchange rate changes on cash and cash equivalents 526 (291)
Net increase in cash and cash equivalents 1,640 4,105
Cash and cash equivalents - beginning of period 10,255 12,928
-------- --------
Cash and cash equivalents - end of period $ 11,895 $ 17,033
======== ========
See accompanying notes.
5
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Consolidated Condensed Statements of Comprehensive Income
(In thousands)
(Unaudited)
Three Months Ended Six Months Ended
April 30, April 30,
------------------ -----------------
2003 2002 2003 2002
------- ------- ------- -------
Net income $15,211 $ 9,918 $29,066 $19,323
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment 1,379 2,361 9,052 (28)
Change in value of derivative instruments 31 383 59 410
Unrealized gain (loss) on marketable securities:
Gain (loss) arising during period 940 (373) 1,118 64
Reclassification adjustment -- (53) -- (738)
------- ------- ------- -------
Unrealized gain (loss) on marketable securities 940 (426) 1,118 (674)
------- ------- ------- -------
Other comprehensive income (loss), net of tax 2,350 2,318 10,229 (292)
------- ------- ------- -------
Comprehensive income $17,561 $12,236 $39,295 $19,031
======= ======= ======= =======
See accompanying notes.
6
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements
(Unaudited)
Note 1. General
The Cooper Companies, Inc. ("Cooper" or "we" and similar pronouns), through its
two business units, develops, manufactures and markets healthcare products.
CooperVision ("CVI") markets a range of specialty contact lenses to correct
visual defects, including toric lenses to correct astigmatism, cosmetic lenses
to change or enhance the appearance of the eyes' natural color, multifocal
lenses designed to correct presbyopia, an age-related vision defect, and lenses
for patients with dry eyes. Its leading products are disposable and planned
replacement toric and spherical lenses. CooperSurgical ("CSI") markets medical
devices, diagnostic products and surgical instruments and accessories used
primarily by gynecologists and obstetricians.
During interim periods, we have followed the accounting policies described in
our Form 10-K for the fiscal year ended October 31, 2002. Please refer to this
and to our Annual Report to Stockholders for the same period when reviewing this
Form 10-Q. Certain prior period amounts have been reclassified to conform to the
current period's presentation. Current results are not a guarantee of future
performance.
The unaudited consolidated condensed financial statements presented in this
report contain all adjustments necessary to present fairly Cooper's consolidated
financial position as of April 30, 2003 and October 31, 2002, the consolidated
results of its operations for the three and six months ended April 30, 2003 and
2002, and its cash flows for the six months ended April 30, 2003 and 2002. All
of these adjustments are normal and recurring.
See "Estimates and Critical Accounting Policies" in Item 2. Management's
Discussion and Analysis of Financial Conditions and Results of Operations.
Note 2. Inventories, at the Lower of Average Cost or Market
April 30, October 31,
2003 2002
--------- -----------
(In thousands)
Raw materials $15,489 $13,176
Work-in-process 16,197 14,067
Finished goods 50,291 49,036
------- -------
$81,977 $76,279
======= =======
7
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements, Continued
(Unaudited)
Note 3. New Accounting Pronouncements
In November 2002, Cooper adopted Financial Accounting Standards Board ("FASB")
Interpretation No. 45 ("FIN 45") "Guarantor's Accounting and Disclosure
Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of
Others." FIN 45 requires a guarantor to recognize, at the inception of a
guarantee, a liability for the fair value of the obligation undertaken by it in
issuing the guarantee. It also requires certain disclosures in the financial
statements of the guarantor with respect to its obligations. The Company has
completed a compliance review and has determined that its implementation of FIN
45 will have no material impact on its financial statements.
Note 4. Accrued Acquisition Costs
When we record acquisitions, we accrue for the estimated costs of severance,
legal, consulting, due diligence, plant/office closure and deferred acquisition
payments. The table below presents the opening balance of accrued acquisition
costs at October 31, 2002, activity recorded in the first six months of fiscal
2003 and the closing balance at April 30, 2003.
Opening Closing
Description Balance Additions Payments Balance
- ----------- ------- --------- -------- -------
(In thousands)
Severance $ 8,965 $ -- $ (3,215) $ 5,750
Legal and consulting 3,542 223 (1,774) 1,991
Plant shutdown 7,807 449 (1,155) 7,101
Hold back due 4,333 1,650 (4,613) 1,370
Pre-acquisition liabilities -- 1,959 (688) 1,271
Other 126 160 (138) 148
------- ------ -------- -------
$24,773 $4,441 $(11,583) $17,631
======= ====== ======== =======
Note 5. Intangible Assets
As of April 30, 2003 As of October 31, 2002
------------------------------ ------------------------------
Accumulated Accumulated
Gross Carrying Amortization Gross Carrying Amortization
Amount & Translation Amount & Translation
-------------- ------------- -------------- -------------
(In thousands)
Other Intangible Assets
Trademarks $ 578 $ 157 $ 578 $ 144
Patents 12,812 4,644 12,711 4,289
License and distribution rights 6,654 1,844 6,654 1,602
Other 1,030 92 778 35
------- ------ ------- ------
$21,074 $6,737 $20,721 $6,070
======= ====== ======= ======
8
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements, Continued
(Unaudited)
We estimate that annual amortization expense will be about $1.5 million per year
in the five-year period ended October 31, 2007.
Goodwill (In thousands)
Balance as of November 1, 2002 $238,966
Goodwill on acquisitions and acquisition adjustments 9,020
Other adjustments* 3,755
--------
$251,741
========
* Primarily translation differences in goodwill denominated in foreign currency.
Note 6. Debt
April 30, October 31,
2003 2002
--------- -----------
(In thousands)
Short-term:
Notes payable to banks $ -- $ 2,519
Current portion of long-term debt 20,636 33,814
-------- --------
$ 20,636 $ 36,333
======== ========
Long-term:
KeyBank line of credit $156,968 $132,310
County of Monroe Industrial Development
Agency bond 1,785 1,899
Capitalized leases 3,518 4,471
Promissory notes - Aspect -- 22,291
Other 307 161
-------- --------
162,578 161,132
Less current portion 20,636 33,814
-------- --------
$141,942 $127,318
======== ========
KeyBank Line of Credit: In December 2002, we used $21 million of our KeyBank
line of credit to retire the Promissory notes - Aspect.
At April 30, 2003, we had $64.7 million available under the KeyBank line of
credit.
(In millions)
Amount of line $ 225.0
Outstanding loans (160.3)*
-------
Available $ 64.7
=======
* Includes $3.3 million in letters of credit backing other debt.
9
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements, Continued
(Unaudited)
Note 7. Earnings Per Share ("EPS")
(In thousands, except for EPS)
Three Months Ended Six Months Ended
April 30, April 30,
------------------ -----------------
2003 2002 2003 2002
------- ------- ------- -------
Net income $15,211 $ 9,918 $29,066 $19,323
======= ======= ======= =======
Basic:
Weighted average common shares 31,003 30,487 30,953 30,452
======= ======= ======= =======
Basic EPS $ 0.49 $ 0.33 $ 0.94 $ 0.63
======= ======= ======= =======
Diluted:
Basic weighted average common shares 31,003 30,487 30,953 30,452
Add dilutive securities:
Stock options 786 641 743 643
------- ------- ------- -------
Denominator for diluted EPS 31,789 31,128 31,696 31,095
======= ======= ======= =======
Diluted EPS $ 0.48 $ 0.32 $ 0.92 $ 0.62
======= ======= ======= =======
We excluded the following options to purchase Cooper's common stock from the
computation of diluted EPS because their exercise prices were above the average
market price:
Three Months Ended Six Months Ended
April 30, April 30,
----------------------------- -----------------------------
2003 2002 2003 2002
------------- ------------- ------------- -------------
Number of shares excluded 374,000 1,055,500 374,000 1,055,500
============= ============= ============= =============
Range of exercise prices $29.50-$31.11 $23.93-$31.11 $29.50-$31.11 $23.93-$31.11
============= ============= ============= =============
Note 8. Income Taxes
Cooper's effective tax rate ("ETR") (provision for income taxes divided by
pretax income) was 25% for the quarter and the six-month period ended April 30,
2003. We adjusted the 2002 six-month period ETR to 27% from the prior quarter's
29%, resulting in an ETR of 25% for the three-months ended April 30, 2002. This
adjustment reflected the favorable effects of the acquisition of Biocompatibles
International plc. at the end of February 2002, which resulted in increased
international operations.
10
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements, Continued
(Unaudited)
Note 9. Accounting for Stock Plans
As permitted by SFAS 123, Cooper applies APB Opinion No. 25 and related
interpretations to account for its plans for stock options issued to employees.
Accordingly, no compensation cost has been recognized for its employee stock
option plans. Had compensation cost for our stock-based compensation plans been
determined under the fair value method included in SFAS 123, as amended by SFAS
148, "Accounting for Stock-Based Compensation - Transition and Disclosure, an
Amendment of FASB Statement No. 123," adopted in the second quarter 2003, our
net income and earnings per share would have been reduced to the pro forma
amounts indicated below:
Three Months Ended Six Months Ended
April 30, April 30,
------------------ -----------------
2003 2002 2003 2002
------- ------ ------- -------
(In thousands)
Net income, as reported $15,211 $9,918 $29,066 $19,323
Deduct: Total stock-based employee compensation
expense determined under fair value based
method for all awards granted since
February 1, 1995, net of related tax effects (3,861) (950) (6,506) (1,860)
------- ------ ------- -------
Pro forma net income 11,350 8,968 22,560 17,463
======= ====== ======= =======
Basic earnings per share:
As reported 0.49 0.33 0.94 0.63
Pro forma 0.37 0.29 0.73 0.57
Diluted earnings per share:
As reported 0.48 0.32 0.92 0.62
Pro forma 0.36 0.29 0.72 0.57
Effective tax rate used to determine pro forma
net income 25% 25% 25% 25%
Note 10. Cash Dividends
We paid a semiannual dividend of 3 cents per share on January 6, 2003 to
stockholders of record on December 16, 2002.
On May 16, 2003, we declared a semiannual dividend of 3 cents per share, payable
on July 3, 2003 to stockholders of record on June 13, 2003.
11
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements, Continued
(Unaudited)
Note 11. Business Segment Information
For management reporting, Cooper is organized by operating business segment with
segment profitability measured primarily by operating income. Corporate expenses
are not allocated to segment operating income. Items accounted for after
operating income are not considered when measuring segment profitability. The
accounting policies used to generate segment results are the same as our overall
accounting policies, which are designed to provide financial statements in
accordance with accounting principles generally accepted in the United States of
America.
Identifiable assets are those assets used in continuing operations excluding
cash and cash equivalents, which we designate as corporate assets. Long-lived
assets are primarily property, plant and equipment, goodwill and other
intangibles.
Segment information (in thousands):
Three Months Ended Six Months Ended
April 30, April 30,
------------------ --------------------
2003 2002 2003 2002
------- ------- -------- --------
Sales to external customers:
CVI $78,045 $56,108 $150,865 $ 98,247
CSI 18,323 15,802 39,517 31,775
------- ------- -------- --------
$96,368 $71,910 $190,382 $130,022
======= ======= ======== ========
Operating income:
CVI $20,141 $12,313 $ 38,520 $ 23,632
CSI 4,011 4,053 7,843 7,586
Corporate (3,000) (1,683) (5,392) (3,428)
------- ------- -------- --------
Total operating income 21,152 14,683 40,971 27,790
Interest expense (1,688) (1,441) (3,512) (2,334)
Other income (expense), net 818 (18) 1,296 1,018
------- ------- -------- --------
Income before income taxes $20,282 $13,224 $ 38,755 $ 26,474
======= ======= ======== ========
April 30, October 31,
2003 2002
--------- -----------
Identifiable assets:
CVI $431,469 $401,421
CSI 115,718 111,998
Corporate 52,978 57,696
-------- --------
Total $600,165 $571,115
======== ========
Goodwill:
CVI $181,294 $170,843
CSI 70,447 68,123
-------- --------
Total $251,741 $238,966
======== ========
12
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements, Continued
(Unaudited)
Geographic information (in thousands):
Three Months Ended Six Months Ended
April 30, April 30,
------------------ -------------------
2003 2002 2003 2002
------- ------- -------- --------
Sales to external customers by
country of domicile:
United States $58,509 $46,920 $115,722 $ 88,878
Europe 28,226 20,780 56,450 33,178
Rest of world 9,633 4,210 18,210 7,966
------- ------- -------- --------
Total $96,368 $71,910 $190,382 $130,022
======= ======= ======== ========
April 30, October 31,
2003 2002
--------- ----------
Long-lived assets by country
of domicile:
United States $166,146 $158,477
Europe 192,248 180,585
Rest of world 5,954 2,499
-------- --------
Total $364,348 $341,561
======== ========
Note 12. Subsequent Events
Prism Acquisition: On May 5, 2003, Cooper completed the acquisition of Prism
Enterprises, LP. Prism develops, manufactures and sells medical devices and
other disposable products for the obstetric, neonatal and gynecological markets.
Cooper paid about $23 million for Prism, which had annual revenue of $8.7
million. Prism products help physicians treat women and infants in labor and
delivery, neonatal and gynecological settings. Its product line includes a
variety of vacuum assisted delivery birthing system pumps and cups, neonatal
heel warmers, exothermic heat packs, gynecological catheters and other
disposable obstetric products.
Disposable products accounted for virtually all of Prism's 2002 revenue. In
2002, disposable vacuum assisted delivery ("VAD") systems accounted for about
60% of Prism's revenue, and its disposable obstetric, neonatal and gynecological
products made up the remainder. These products support the perinatal period -
three months before birth to one month after birth - and include heating
products, uterine infusion catheters, bellybands and amniotic hooks.
13
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Notes to Consolidated Condensed Financial Statements, Concluded
(Unaudited)
Litigation Settlement: On April 25, 2001, Dioptics Medical Products, Inc. filed
a lawsuit against Cooper, CVI and A. Thomas Bender in the United States District
Court, Northern District of California, Case No. C01-20356-JW. This lawsuit
alleged that CVI's CV Encore family of contact lenses infringed Dioptics' ENCORE
trademark for sunglasses. The Company believes that it did not infringe any
valid and protectable trademark held by Dioptics. Nevertheless, to avoid ongoing
legal costs and management distraction, Cooper entered into a Confidential
Settlement Agreement on May 5, 2003. The Company recorded a settlement provision
in the first fiscal quarter of 2003 that covers all expected liabilities.
14
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
Note numbers refer to "Notes to Consolidated Condensed Financial Statements"
beginning on page 7 of this report.
Forward-Looking Statements: Some of the information included in this Form 10-Q
contains "forward-looking statements" as defined by the Private Securities
Litigation Reform Act of 1995. These include statements about to our capital
resources, performance and results of operations. In addition, all statements
regarding anticipated growth in our revenue, anticipated market conditions and
results of operations are forward-looking. To identify these statements look for
words like "believes," "expects," "may," "will," "should," "seeks," "intends,"
"plans," "estimates" or "anticipates" and similar words or phrases. Discussions
of strategies, plans or intentions often contain forward-looking statements.
Forward-looking statements necessarily depend on assumptions, data or methods
that may be incorrect or imprecise.
Events, among others, that could cause actual results and future actions to
differ materially from those described in forward-looking statements include
major changes in business conditions, a major disruption in the operations of
our manufacturing facilities, new competitors or technologies, significant
delays in new product introductions, the impact of an undetected virus on our
computer systems, acquisition integration delays or costs, increases in interest
rates, foreign currency exchange exposure, investments in research and
development and other start-up projects, dilution to earnings per share from
acquisitions or issuing stock, regulatory issues, cost of complying with new
corporate governance regulatory requirements, changes in tax laws or their
interpretation, changes in geographical profit mix effecting tax rates,
significant environmental cleanup costs above those already accrued, litigation
costs including any related settlements or judgments, cost of business
divestitures, the requirement to provide for a significant liability or to write
off a significant asset, changes in accounting principles or estimates, and
other factors described in our Securities and Exchange Commission filings,
including the "Business" section in our Annual Report on Form 10-K for the year
ended October 31, 2002. We caution investors that forward-looking statements
reflect our analysis only on their stated date. We disclaim any intent to update
them except as required by law.
Results of Operations
In this section we discuss the results of our operations for the second quarter
and six months of fiscal 2003 and compare them with the same periods of fiscal
2002. We discuss our cash flows and current financial condition beginning on
page 23 under "Capital Resources and Liquidity."
Second Quarter Highlights vs. 2002's Second Quarter:
o Sales up 34% to $96.4 million
o Gross profit up 41%; margin up 4 percentage points to 65% of revenue
o Operating income up 44% to $21.2 million
o Diluted earnings per share up 50% to 48 cents from 32 cents
15
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
Six-Month Highlights:
o Sales up 46% to $190.4 million
o Gross profit up 49% on margin of 64%, up 1 percentage point from last year
o Operating income up 47% to $41 million
o Diluted earnings per share up 48% to 92 cents from 62 cents
Selected Statistical Information - Percentage of Sales and Growth
Percent of Sales Percent of Sales
Three Months Ended Six Months Ended
April 30, April 30,
------------------ % ----------------- %
2003 2002 Growth 2003 2002 Growth
---- ---- ------ ---- ---- ------
Net sales 100% 100% 34% 100% 100% 46%
Cost of sales 35% 39% 22% 36% 37% 42%
Gross profit 65% 61% 41% 64% 63% 49%
Selling, general and administrative 41% 39% 41% 41% 40% 51%
Research and development 1% 1% 39% 1% 1% 46%
Amortization 1% 1% 2% --% 1% 8%
Operating income 22% 20% 44% 22% 21% 47%
Net Sales: Cooper's two business units, CooperVision ("CVI") and CooperSurgical
("CSI") generate all our revenue:
o CVI markets a broad range of soft contact lenses for the vision care market
worldwide.
o CSI markets medical devices, diagnostic products and surgical instruments
and accessories used primarily by gynecologists and obstetricians.
Our consolidated net sales grew $24.5 million (34%) in the three-month period
and $60.4 million (46%) in the six-month period:
Three Months Ended Six Months Ended
April 30, April 30,
----------------------- --------------------------
2003 2002 % Incr. 2003 2002 % Incr.
----- ----- ------- ------ ------ -------
($ in millions)
CVI $78.1 $56.1 39% $150.9 $ 98.2 54%
CSI 18.3 15.8 16% 39.5 31.8 24%
----- ----- ------ ------
$96.4 $71.9 34% $190.4 $130.0 46%
===== ===== ====== ======
Practitioner and patient preferences in the worldwide contact lens market
continue to change. The major shifts are from:
o Conventional lenses replaced annually to disposable and frequently replaced
lenses. Disposable lenses are designed for either daily or two-week
replacement; frequently replaced lenses are designed for replacement after
one to three months.
16
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
o Commodity lenses to specialty lenses including toric lenses, cosmetic
lenses, multifocal lenses and lenses for patients with dry eyes.
o Commodity spherical lenses to value added spherical lenses such as lenses
with aspherical optical properties.
These shifts favor CVI's line of specialty products (now about 60% of CVI's
revenue).
Soft Lens Revenue: CVI's worldwide soft contact lens revenue - all revenue
except royalty revenue and miscellaneous items - grew 42% and 56% for the three-
and six-month periods, respectively; 34% and 49% in constant currency. Revenue
from Biocompatibles Eye Care, Inc. ("Biocompatibles"), which we acquired on
February 28, 2002, paced the increase. Excluding Biocompatibles soft lens
revenue of $45.2 million and $37.3 million in the six-month period for fiscal
2003 and 2002, respectively, total soft lens revenue grew 24% and 20% in
constant currency. The primary reasons for this include continued global market
share gains in our toric products, up 23% in the quarter, continued momentum in
Europe, up 25% in the quarter, and growth in disposable spheres, up 43% in the
quarter.
CVI reported revenue includes Biocompatibles beginning in March 2002. In the
following table we adjust CVI reported revenue by adding to it the
Biocompatibles revenue for the three- and six-month periods ended April 30, 2002
as shown on the Biocompatibles' unaudited ledgers for those periods. This shows
the growth in the total lens business we now own. Adjusted soft lens revenue
grew 29% in the three-month period and 23%, in the six-month period ended April
30, 2003.
Since the acquisition of Biocompatibles, CVI has actively promoted Proclear
lenses. In many cases, practitioners now recommend Proclear lenses rather than
older CVI products.
Definitions: Soft lens revenue includes sales of spherical lenses, which include
aspherically designed lenses, and specialty lenses - toric, cosmetic, multifocal
lenses and lenses for patients with dry eyes.
o Aspheric lenses correct only for near- and farsightedness, but they have
additional optical properties that help improve visual acuity in low light
conditions and can correct low levels of astigmatism and low levels of
presbyopia, an age-related vision defect.
o Toric lenses are designed to correct astigmatism by adding the additional
optical properties of cylinder and axis.
o Cosmetic lenses are opaque and color enhancing lenses that alter the
natural appearance of the eye.
o Multifocal lenses are designed to correct presbyopia.
o Proclear lenses help enhance tissue-device compatibility for patients
experiencing mild discomfort relating to dry eyes during lens wear.
17
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
CVI Revenue:
Second Quarter Six Months
-------------- --------------
Reported: 2003 2002 Growth 2003 2002 Growth
----- ----- ------ ------ ----- ------
($ in millions)
U.S. $39.7 $30.2 31% $ 73.9 $55.0 34%
International 36.3 23.3 56% 71.3 37.9 88%
----- ----- ------ -----
Soft lens revenue 76.0 53.5 42% 145.2 92.9 56%
Miscellaneous revenue 2.1 2.6 (24%) 5.7 5.3 6%
----- ----- ------ -----
Total reported $78.1 $56.1 39% $150.9 $98.2 54%
===== ===== ====== =====
Adjustments - to include Biocompatibles revenue for comparable periods:
2002 2002
---- -----
($ in millions)
U.S. $1.1 $ 6.3
International 4.2 18.5
---- -----
Soft lens revenue 5.3 24.8
Miscellaneous revenue 0.2 0.3
---- -----
Total reported $5.5 $25.1
==== =====
Second Quarter Six Months
-------------- ---------------
As adjusted: 2003 2002 Growth 2003 2002 Growth
----- ----- ------ ------ ------ ------
($ in millions)
U.S. $39.7 $31.3 27% $ 73.9 $ 61.3 21%
International 36.3 27.5 32% 71.3 56.4 26%
----- ----- ------ ------
Soft lens revenue 76.0 58.8 29% 145.2 117.7 23%
Miscellaneous revenue 2.1 2.8 (30%) 5.7 5.6 1%
----- ----- ------ ------
Total as adjusted $78.1 $61.6 27% $150.9 $123.3 22%
===== ===== ====== ======
Total adjusted worldwide revenue grew 27% and 22% (about 20% and 16% in constant
currency) for the three- and six-month periods. Adjusted international soft lens
revenue of $36.3 million grew 32% (16% in constant currency) for the three-month
period.
The 32% and 26% growth in reported international soft lens revenue, from $27.5
million and $56.4 million to $36.3 million and $71.3 million in the three- and
six-month periods, respectively, was largely driven by sales of two-week and
monthly sphere products, which grew $6.3 million, or 47%, and $11.4 million, or
43%, in the three- and six-months periods, respectively. Also, sales of two-week
and monthly toric products grew $2 million, or 41%, and $2.8 million, or 27%, in
the three- and six-month periods, respectively.
18
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
Adjusted soft lens revenue in the United States grew 27% in the second quarter
and 21% in the first half of fiscal 2003, primarily due to sales of two-week and
monthly sphere products, which added $3.9 million, growing 39%, and $5.8
million, growing 29%, in the three- and six-month periods, respectively. Also,
sales of two-week and monthly toric products added $3.5 million, growing 53%,
and $5.8 million, growing 46%, in the three- and six-month periods,
respectively. The acquisition of Biocompatibles enhanced the growth in these
product lines, especially the sales of Proclear toric and other specialty
lenses.
CSI Revenue: Women's healthcare products used primarily by obstetricians and
gynecologists generate about 90% of CSI's revenue. The balance represents sales
of medical devices outside of women's healthcare that CSI does not actively
market. CSI's overall second quarter revenue increased 16% to $18.3 million. The
acquisitions of Norland Medical Systems in April 2002, Ackrad Laboratories, Inc.
in May 2002 and Sage BioPharma, Inc. in October 2002, generated most of the
growth, which was partially offset by declining sales in more mature product
lines.
Cost of Sales/Gross Profit: Gross profit as a percentage of sales ("gross
margin") was as follows:
Margin % Margin %
Three Months Ended Six Months Ended
April 30, April 30,
------------------ ----------------
2003 2002 2003 2002
---- ---- ---- ----
CVI 67% 63% 67% 66%
CSI 53% 55% 52% 54%
Consolidated 65% 61% 64% 63%
CVI's gross margin for the second quarter of fiscal 2003 was 67%, compared with
63% for the second quarter last year. The increase was primarily due to cost
reductions and the shift to specialty lenses. CVI manufactures a major
percentage of its lenses in the United Kingdom. The favorable impact of currency
on revenue is offset by the unfavorable impact on manufacturing costs. In
addition, we have lower gross margin on sales to Asia-Pacific distributors. Last
year's gross margin reflects lower gross margin sales of certain Biocompatibles'
products. Biocompatibles' gross margin improved as CVI improved manufacturing
costs and continues to shift customers to higher gross margin Proclear products.
CSI's gross margin was 53%, compared with 55% for the second quarter last year,
because sales of recent acquisitions' products, which have expanded our product
line in the area of infertility, currently have lower gross margins. We expect
gross margin to continue to improve as we integrate the new operations.
19
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
Selling, General and Administrative ("SGA") Expense:
Three Months Ended Six Months Ended
April 30, April 30,
-------------------------------- --------------------------------
2003 % Rev. 2002 % Incr. 2003 % Rev. 2002 % Incr.
----- ------ ----- ------- ----- ------ ----- -------
($ in millions)
CVI $31.4 40% $22.3 41% $60.7 40% $39.1 55%
CSI 5.2 28% 4.2 23% 11.4 29% 8.9 29%
Headquarters 3.0 -- 1.7 78% 5.4 -- 3.4 57%
----- ----- ----- -----
$39.6 41% $28.2 41% $77.5 41% $51.4 51%
===== ===== ===== =====
Consolidated SGA increased 41%, and as a percentage of revenue, grew from 39% to
41% for the three-month period and from 40% to 41% for the six-month period due
primarily to acquisitions, which contributed to the 34% and 46% increase in
revenue for the three- and six-month periods, respectively. About $1.8 million
and $3.2 million of the SGA increase in the three- and six-month periods,
reflected the relative weakness of the U.S. dollar against foreign currencies.
Corporate headquarters' expenses, which increased 25% sequentially and 78% over
last year's second quarter, include spending to support the Company's ongoing
tax planning. These expenses are expected to level off and then decrease after
2003. Going forward, Cooper expects to incur increased headquarters' expenses to
comply with recent corporate governance requirements.
Research and Development ("R&D") Expense: During the first half of fiscal 2003,
CVI R&D expenditures were $1.7 million, up 36% over the first half of 2002,
reflecting the previously announced initiative to develop new and improved
contact lens products. During the 2003 to 2005 period, CVI is investing in two
new research programs: the development of an extended wear contact lens and an
improved contact lens technology. We expect R&D expense of about $4 million in
2003. CSI R&D expenditures in the first six months of fiscal 2003 were up about
$360,000, or 72%, primarily because of R&D projects of acquired companies.
Amortization of Intangibles: Amortization expense increased to $399,000 and
$755,000 in the three and six months of fiscal 2003 from $392,000 and $700,000
in last year's three- and six-month periods.
20
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
Operating Income: Operating income improved by $6.5 million, or 44%, and $13.2
million, or 47%, for the three- and six-month periods, respectively:
Three Months Ended Six Months Ended
April 30, April 30,
-------------------------------- --------------------------------
2003 % Rev. 2002 % Incr. 2003 % Rev. 2002 % Incr.
----- ------ ----- ------- ----- ------ ----- -------
($ in millions)
CVI $20.2 26% $12.3 64% $38.5 26% $23.6 63%
CSI 4.0 22% 4.1 (1%) 7.9 20% 7.6 3%
Headquarters (3.0) -- (1.7) -- (5.4) -- (3.4) --
----- ----- ----- -----
$21.2 22% $14.7 44% $41.0 22% $27.8 47%
===== ===== ===== =====
Interest Expense: Interest expense increased $247,000, or 17%, in the
three-month period and $1.2 million, or 50%, in the six-month period, primarily
due to increased borrowings for acquisitions, partially offset by lower interest
rates.
Other Income (Expense), Net:
Three Months Ended Six Months Ended
April 30, April 30,
------------------ ----------------
2003 2002 2003 2002
----- ----- ------ ------
(In thousands)
Interest income $ 55 $ 43 $ 89 $ 78
Foreign exchange transactions 557 (154) 1,621 (174)
Settlement of dispute -- -- (500) --
Gain on sale of Quidel stock -- 100 -- 1,128
Other 206 (7) 86 (14)
----- ----- ------ ------
$ 818 $ (18) $1,296 $1,018
===== ===== ====== ======
In conjunction with the acquisition of Biocompatibles, we inherited intercompany
accounts in various currencies, primarily pounds sterling. The pound
strengthened against the dollar in the first half of 2003, resulting in a net
gain of about $1.6 million. We have taken steps to minimize this exposure. Our
policy continues to be to hedge foreign exchange exposure whenever possible.
In the first quarter of 2003, we provided $500,000 for the potential settlement
of a legal dispute.
In the first half of 2002, we sold 542,000 shares of Quidel stock, realizing a
gain of approximately $1.1 million.
21
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
Provision for Income Taxes: We estimate that our effective tax rate ("ETR") for
fiscal year 2003 will be 25%, down from 27% for the first six months of 2002.
The reduction of our ETR resulted from a higher percentage of our income coming
from international operations (including the international operations at
Biocompatibles).
We implemented a global trading arrangement in fiscal 1999 to minimize both the
taxes reported in our statement of income and the actual taxes we will have to
pay when we exhaust all the benefits of our net operating loss carryforwards
("NOLs").
The global trading arrangement consists of a restructuring of the legal
ownership structure for the CooperVision foreign sales and manufacturing
subsidiaries. The stock of those subsidiaries is now owned by a single foreign
holding company, which centrally directs much of the activities of those
subsidiaries. The foreign holding company has applied for and received the
benefits of a reduced tax rate under a special tax regime available in its
country of residence.
On February 28, 2002, the Company acquired Biocompatibles. Assuming no other
major acquisitions or large stock issuances, we currently expect that this plan
will extend the cash flow benefits of the NOLs through 2006, and that actual
cash payments of taxes will average less than 5% of pretax profits over this
period. After 2006, actual cash payments of income taxes are expected to average
less than 20% of pretax profits.
22
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
Capital Resources & Liquidity
Second Quarter Highlights:
o Operating cash flow $27 million vs. $20.5 million in 2002's second quarter
o "Cash flow" (pretax income from continuing operations plus depreciation and
amortization) per diluted share $0.73 vs. $0.52 in 2002's second quarter
o Cash payments for acquisitions totaled $6.3 million
o Expenditures for purchases of property, plant and equipment ("PP&E") $7.5
million vs. $5.7 million in 2002's second quarter
Six-Month Highlights:
o Operating cash flow $30.1 million vs. $24.7 million in the first half of
2002
o Cash flow per diluted share $1.41 vs. $1.02 in the first half of 2002
o Cash payments for acquisitions totaled $38.5 million
o Expenditures for purchases of PP&E $13.4 million vs. $12 million in the
first half of 2002
Comparative Statistics (dollars in millions, except per share amounts):
April 30, 2003 October 31, 2002
-------------- ----------------
Cash and cash equivalents $ 11.9 $ 10.3
Total assets $ 600.2 $ 571.1
Working capital $ 106.9 $ 72.2
Total debt $ 162.6 $ 163.7
Stockholders' equity $ 353.1 $ 311.4
Ratio of debt to equity 0.46:1 0.53:1
Debt as a percentage of total capitalization 32% 34%
Operating cash flow - twelve months ended $ 61.4 $ 55.9
Cash flow per diluted share - twelve months ended $ 2.84 $ 2.45
Operating Cash Flows: Our major source of liquidity continues to be cash flow
provided by operating activities, which totaled $30.1 million in the first half
of fiscal 2003 and $61.4 million over the twelve-month period ended April 30,
2003.
Major uses of cash for operating activities in the first six months included
payments of $4.5 million to settle the dispute with Medical Engineering
Corporation, a subsidiary of Bristol-Myers Squibb Company, pursuant to a 1993
settlement agreement, $2.6 million to fund entitlements under Cooper's bonus
plans and $3.1 million in interest payments.
23
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
Our working capital increased by $34.7 million in the first half of fiscal 2003,
driven by foreign exchange rates, which impacted the increases in trade
receivables and inventory and the reduction of about $15.7 million of short-term
debt. At the end of the second fiscal quarter, Cooper's days sales outstanding
("DSO's") decreased to 71 days from 79 days last quarter reflecting improved
cash collections. DSO's are expected in the low to mid-70's through the
remainder of fiscal 2003.
Investing Cash Flows: The cash outflow of $52 million from investing activities
was caused by capital expenditures of $13.4 million and payments of $38.5
million on acquisitions including $22.4 million paid to the Aspect noteholders,
the final payment for the Aspect acquisition.
Financing Cash Flows: Financing activities provided $22.9 million of cash,
primarily from net borrowing from our credit facility of $23.2 million. Cash
received from the exercises of stock options provided $3.3 million. We repaid
net other debt of about $2.6 million. We paid dividends on our common stock of
$927,000 in the first fiscal quarter of 2003.
24
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
Estimates and Critical Accounting Policies
Estimates and judgments made by Management are an integral part of financial
statements prepared in accordance with accounting principles generally accepted
in the United States of America ("GAAP"). Actual results may be different from
amounts reported for or at the end of any period. We believe that the following
critical accounting policies address the more significant estimates required of
Management when preparing our consolidated financial statements in accordance
with GAAP:
o Revenue recognition - In general, we recognize revenue upon shipment of our
products, when risk of ownership transfers to our customers. We record,
based on historical statistics, appropriate provisions for shipments to
customers who have the right of return.
o Adequacy of allowance for doubtful accounts - In accordance with GAAP, our
reported balance of accounts receivable, net of the allowance for doubtful
accounts, represents our estimate of the amount that ultimately will be
realized in cash. We review the adequacy of our allowance for doubtful
accounts on an ongoing basis, using historical payment trends and the age
of the receivables, complemented by individual knowledge of our customers.
If and when our analyses indicate, we increase or decrease our allowance
accordingly.
o Net realizable value of inventory - GAAP states that inventories be stated
at the lower of cost or market value, or "net realizable value." On an
ongoing basis, we review the carrying value of our inventories, measuring
number of months on hand and other indications of salability and, when
indicated, reduce the value of inventory if there are indications that the
carrying value is greater than market.
o Valuation of goodwill - We record and evaluate our goodwill balances and
test them for impairment in accordance with the provisions of Statements of
Financial Accounting Standards 141, "Business Combinations" and No. 142,
"Goodwill and Other Intangible Assets," respectively.
o Income taxes - As part of the process of preparing our consolidated
financial statements, we are required to estimate our income taxes in each
of the jurisdictions in which we operate. This process involves estimating
our current tax exposures in each jurisdiction including the impact, if
any, of additional taxes resulting from tax examinations as well as making
judgments regarding the recoverability of deferred tax assets. To the
extent recovery of deferred tax assets is not likely based on our
estimation of future taxable income in each jurisdiction, a valuation
allowance is established. Tax exposures can involve complex issues and may
require an extended period to resolve. To determine the quarterly tax rate,
we are required to estimate full-year income and the related income tax
expense in each jurisdiction. The estimated effective tax rate is adjusted
for the tax related to significant unusual items. Changes in the geographic
mix or estimated level of annual pre-tax income can affect the overall
effective tax rate.
25
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
Non-GAAP Financial Measure
Cooper's earnings before taxes, depreciation and amortization ("cash flow") per
share for the second quarter of fiscal 2003 was 73 cents and 52 cents for the
second quarter of 2002. For the six months ended April 30, cash flow per share
was $1.41 and $1.02 per share in 2003 and 2002, respectively.
Although "cash flow per share" is a non-GAAP financial measure, we disclose it
because we think it is an appropriate measure of our liquidity and financial
strength, particularly when calculated consistently over time. Cooper has been
reporting "cash flow per share" since 1999.
In Cooper's case, earnings before taxes, depreciation and amortization per share
is more informative than the more common non-GAAP measure of liquidity called
"earnings before interest, taxes, depreciation and amortization." This is
because, unlike most companies, Cooper does not anticipate paying federal income
taxes (except for alternative minimum taxes reinstated beginning in 2003) until
about 2007, when it expects to exhaust its U.S. net operating loss
carryforwards. This cash savings gives Cooper a significant competitive
advantage, as most companies spend a large portion of their pretax profits on
taxes.
Cash flow per share is not a substitute for the GAAP measure of operating cash
flow. We present this data to increase awareness that income taxes provided for
in our statement of income are essentially all noncash provisions which go
toward reducing our recorded deferred tax asset in accordance with generally
accepted accounting principles.
To calculate "cash flow per share," we add back non-cash charges for
depreciation and amortization to income before income taxes, and then divide the
result by the average number of shares outstanding used to calculate diluted
earnings per share. In the tables below, we reconcile earnings per share (the
closest GAAP disclosure) to "cash flow per share" for all periods reported using
the same diluted per share figures.
Three Months Ended April 30,
-----------------------------------------
2003 2002
------------------- -------------------
$(000) Per Share $(000) Per Share
------- --------- ------- ---------
Net income $15,211 $0.48 $ 9,918 $0.32
===== =====
Add:
Income taxes 5,071 3,306
Depreciation 2,578 2,660
Amortization 399 392
------- -------
"Cash flow per share" $23,259 $0.73 $16,276 $0.52
======= ===== ======= =====
Shares (000) 31,789 31,128
======= =======
26
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Continued
Six Months Ended April 30,
-----------------------------------------
2003 2002
------------------- -------------------
$(000) Per Share $(000) Per Share
------- --------- ------- ---------
Net income $29,066 $0.92 $19,323 $0.62
===== =====
Add:
Income taxes 9,689 7,151
Depreciation 5,193 4,445
Amortization 755 700
------- -------
"Cash flow per share" $44,703 $1.41 $31,619 $1.02
======= ===== ======= =====
Shares (000) 31,696 31,095
======= =======
12 Months Ended
October 31, 2002
-------------------
$(000) Per Share
------- ---------
Year ended October 31, 2002:
Net income $48,875 $ 1.57
======
Add:
Income taxes 16,294
Depreciation 9,892
Amortization 1,477
-------
"Cash flow per share" $76,538 $ 2.45
======= ======
Shares (000) 31,189
=======
Trailing twelve months ended April 30, 2003:
Twelve months ended October 31, 2002 $ 2.45
Less: six months ended April 30, 2002 (1.02)
Add: six months ended April 30, 2003 1.41
------
"Cash flow per share" for the 12 months
ended April 30, 2003 $ 2.84
======
27
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations, Concluded
Outlook
We believe that cash and cash equivalents on hand of $11.9 million plus cash
from operating activities will fund future operations, capital expenditures,
cash dividends and smaller acquisitions. At April 30, 2003, we had $64.7 million
available under the KeyBank line of credit, and based on conceptual discussions
within the banking community, anticipate that we could raise additional debt if
required.
Risk Management
We are exposed to risks caused by changes in foreign exchange, principally pound
sterling and euro denominated debt and receivables and from operations in
foreign currencies. We have taken steps to minimize our exposure. We are also
exposed to risks associated with changes in interest rates, as the interest rate
on most of our debt varies with the London Interbank Offered Rate. There have
been no material changes in sensitivity to market risk in the six-month period
ended April 30, 2003.
Trademarks
Proclear'r'is a registered trademark of The Cooper Companies, Inc., its
affiliates and/or subsidiaries and is italicized in this report. CV Encore
Toric'TM' and Xcel'TM' are trademarks of The Cooper Companies, Inc., its
affiliates and subsidiaries and are italicized in this report.
28
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Item 3. Quantitative and Qualitative Disclosure About Market Risk
Item 3. Quantitative and Qualitative Disclosure About Market Risk
See Capital Resources and Liquidity under "Risk Management" in Item 2 of this
report.
Item 4. Controls and Procedures
The Company has established and currently maintains disclosure controls and
procedures designed to ensure that material information required to be disclosed
in its reports filed under the Securities Exchange Act of 1934 is recorded,
processed, summarized and reported, within the time periods specified by the
Securities and Exchange Commission and that any material information relating to
the Company is recorded, processed, summarized and reported to its principal
officers to allow timely decisions regarding required disclosures. In designing
and evaluating the disclosure controls and procedures, management recognized
that any controls and procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving the desired control objectives,
and in reaching a reasonable level of assurance, management necessarily was
required to apply its judgment in evaluating the cost-benefit relationship of
possible controls and procedures.
In conjunction with the close of each fiscal quarter, the Company conducts a
review and evaluation of the effectiveness of the Company's disclosure controls
and procedures. The Company's Chief Executive Officer and President, based upon
an evaluation completed within 90 days prior to the filing of this report, has
concluded that the Company's disclosure controls and procedures are effective.
There have been no significant changes in the Company's internal controls or in
other factors that could significantly affect internal controls subsequent to
April 30, 2003.
29
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
The information required by this item is incorporated herein by reference to
"Litigation Settlement" under Note 12 of Notes to Consolidated Condensed
Financial Statements in Part I, Item I of this report.
Item 4. Submission of Matters to a Vote of Security Holders
The 2003 Annual Meeting of Stockholders was held on March 25, 2003.
Each of the eight individuals nominated to serve as directors of the Company was
elected:
Director Shares For Shares Against
- -------- ---------- --------------
A. Thomas Bender 28,548,527 791,494
Michael H. Kalkstein 28,189,577 1,150,444
Moses Marx 29,011,713 328,308
Donald Press 28,316,735 1,023,286
Steven Rosenberg 28,189,405 1,150,616
Allan E. Rubenstein, M.D. 28,316,711 1,023,310
Robert S. Weiss 29,011,723 328,298
Stanley Zinberg, M.D. 28,189,547 1,150,474
Stockholders ratified the appointment of KPMG LLP as Cooper's independent
certified public accountant for the fiscal year ending October 31, 2003. A total
of 27,813,936 shares were voted in favor of the ratification, 1,512,862 shares
were voted against it and 13,222 shares abstained.
Stockholders adopted Cooper's Amended and Restated 2001 Long Term Incentive
Plan. A total of 19,467,533 shares were voted in favor of the adoption,
4,975,410 shares were voted against it and 73,671 shares abstained.
Stockholders also approved the amendment to Cooper's Restated Certificate of
Incorporation increasing the number of authorized shares of common stock. A
total of 27,022,014 shares were voted in favor, 2,282,091 shares were voted
against it and 35,913 shares abstained.
30
PART II - OTHER INFORMATION -- Continued
Item 6. Exhibits and Reports on Form 8-K
- ----------------------------------------
(a) Exhibits.
Exhibit
Number Description
------- -----------
3.1 Fourth Certificate of Amendment of Restated Certificate of
Incorporation filed with the Delaware Secretary of State
on March 26, 2003, incorporated by reference to Exhibit 4.5
to our Registration Statement on Form S-8 filed with the
Securities and Exchange Commission on April 7, 2003.
10.1 The Cooper Companies, Inc. Amended and Restated 2001 Long
Term Incentive Plan, incorporated by reference to Exhibit A
to our Proxy Statement for our Annual Meeting of stockholders
held on March 25, 2003 on Form 14A filed with the Securities
and Exchange Commission on February 7, 2003.
10.2 Amendment No. 1 to the Amended and Restated 2001 Long Term
Incentive Plan
11* Calculation of Earnings Per Share
99.1 Certification of Chief Executive Officer
99.2 Certification of Chief Financial Officer
* The information called for in this Exhibit is provided in Footnote 7
to the Consolidated Condensed Financial Statements in this report.
(b) Cooper filed the following reports on Form 8-K during the period from
February 1, 2003 to April 30, 2003.
Date of Report Item Reported
----------------- --------------------
January 30, 2003 Item 5. Other Events
February 26, 2003 Item 5. Other Events
March 25, 2003 Item 5. Other Events
April 28, 2003 Item 5. Other Events
31
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
The Cooper Companies, Inc.
-------------------------------------------
(Registrant)
Date: June 6, 2003 /s/ Stephen C. Whiteford
--------------------------------------------
Stephen C. Whiteford
Vice President and Corporate Controller
(Principal Accounting Officer)
32
CERTIFICATIONS
I, A. Thomas Bender, Chairman of the Board, President and Chief Executive
Officer, certify that:
1. I have reviewed this quarterly report on Form 10-Q of The Cooper Companies,
Inc. (the "registrant");
2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) Designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this quarterly report is being
prepared;
b) Evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and
c) Presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent function):
a) All significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and
b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
controls; and
6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.
Date: June 6, 2003
/s/ A. Thomas Bender
------------------------------------------------------------
A. Thomas Bender
Chairman of the Board, President and Chief Executive Officer
33
CERTIFICATIONS
I, Robert S. Weiss, Executive Vice President and Chief Financial Officer,
certify that:
1. I have reviewed this quarterly report on Form 10-Q of The Cooper Companies,
Inc. (the "registrant");
2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) Designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this quarterly report is being
prepared;
b) Evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90 days prior to the filing date of this
quarterly report (the "Evaluation Date"); and
c) Presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our
evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent function):
a) All significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and
b) Any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
controls; and
6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.
Date: June 6, 2003
/s/ Robert S. Weiss
----------------------------------------------------
Robert S. Weiss
Executive Vice President and Chief Financial Officer
34
THE COOPER COMPANIES, INC. AND SUBSIDIARIES
Index of Exhibits
-----------------
Exhibit No.
- -----------
3.1 Fourth Certificate of Amendment of Restated Certificate of
Incorporation filed with the Delaware Secretary of State
on March 26, 2003, incorporated by reference to Exhibit 4.5
to our Registration Statement on Form S-8 filed with the
Securities and Exchange Commission on April 7, 2003.
10.1 The Cooper Companies, Inc. Amended and Restated 2001 Long
Term Incentive Plan, incorporated by reference to Exhibit A
to our Proxy Statement for our Annual Meeting of stockholders
held on March 25, 2003 on Form 14A filed with the Securities
and Exchange Commission on February 7, 2003.
10.2 Amendment No. 1 to the Amended and Restated 2001 Long Term
Incentive Plan
11* Calculation of Earnings Per Share
99.1 Certification of Chief Executive Officer
99.2 Certification of Chief Financial Officer
* The information called for in this Exhibit is provided in Footnote 7 to the
Consolidated Condensed Financial Statements in this report.
35